Sayeski PP - Search Results

1

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.

Sayyah J, Sayeski PP. Sayyah J, et al. Among authors: sayeski pp. Curr Oncol Rep. 2009 Mar;11(2):117-24. doi: 10.1007/s11912-009-0018-2. Curr Oncol Rep. 2009. PMID: 19216843 Free PMC article. Review.

2

Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth.

Sayyah J, Magis A, Ostrov DA, Allan RW, Braylan RC, Sayeski PP. Sayyah J, et al. Among authors: sayeski pp. Mol Cancer Ther. 2008 Aug;7(8):2308-18. doi: 10.1158/1535-7163.MCT-08-0279. Mol Cancer Ther. 2008. PMID: 18723478 Free PMC article.

3

Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation.

Sayyah J, Gnanasambandan K, Kamarajugadda S, Tsuda S, Caldwell-Busby J, Sayeski PP. Sayyah J, et al. Among authors: sayeski pp. Cell Signal. 2011 Nov;23(11):1806-15. doi: 10.1016/j.cellsig.2011.06.015. Epub 2011 Jun 29. Cell Signal. 2011. PMID: 21726629 Free PMC article.

4

The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor.

Godeny MD, Sayyah J, VonDerLinden D, Johns M, Ostrov DA, Caldwell-Busby J, Sayeski PP. Godeny MD, et al. Among authors: sayeski pp. Cell Signal. 2007 Mar;19(3):600-9. doi: 10.1016/j.cellsig.2006.08.010. Epub 2006 Sep 1. Cell Signal. 2007. PMID: 17027227

5

Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.

Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Kiss R, et al. Among authors: sayeski pp. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3598-601. doi: 10.1016/j.bmcl.2009.04.138. Epub 2009 May 5. Bioorg Med Chem Lett. 2009. PMID: 19447617 Free PMC article.

6

The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors.

Baskin R, Majumder A, Sayeski PP. Baskin R, et al. Among authors: sayeski pp. Curr Med Chem. 2010;17(36):4551-8. doi: 10.2174/092986710794182953. Curr Med Chem. 2010. PMID: 21062251 Free PMC article. Review.

7

A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Gnanasambandan K, Sayeski PP. Gnanasambandan K, et al. Among authors: sayeski pp. Curr Med Chem. 2011;18(30):4659-73. doi: 10.2174/092986711797379267. Curr Med Chem. 2011. PMID: 21864276 Free PMC article. Review.

8

Jak2 tyrosine kinase and cancer: how good cells get HiJAKed.

Godeny MD, Sayeski PP. Godeny MD, et al. Among authors: sayeski pp. Anticancer Agents Med Chem. 2007 Nov;7(6):643-50. doi: 10.2174/187152007782330105. Anticancer Agents Med Chem. 2007. PMID: 18045059 Review.

9

Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.

Majumder A, Govindasamy L, Magis A, Kiss R, Polgár T, Baskin R, Allan RW, Agbandje-McKenna M, Reuther GW, Keseru GM, Bisht KS, Sayeski PP. Majumder A, et al. Among authors: sayeski pp. J Biol Chem. 2010 Oct 8;285(41):31399-407. doi: 10.1074/jbc.M110.168211. Epub 2010 Jul 28. J Biol Chem. 2010. PMID: 20667821 Free PMC article.

10

The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617.

Gnanasambandan K, Magis A, Sayeski PP. Gnanasambandan K, et al. Among authors: sayeski pp. Biochemistry. 2010 Nov 23;49(46):9972-84. doi: 10.1021/bi1014858. Epub 2010 Oct 29. Biochemistry. 2010. PMID: 20958061 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page